Recently, BioAge Labs, a biotechnology company focused on obesity treatment, announced officially thatThe U.S. Securities and Exchange Commission submitted an IPO application, aiming to raise 100 million U.S. dollars.Will be listed on NASDAQ under the stock code "BIOA".The company is in the clinical stage, and its main candidate drug, azelaprag, is an oral small molecule drug expected to enter phase two trials in the first half of next year in combination with semaglutide (sold by Novo Nordisk under the brand name Wegovy for weight loss). Semaglutide has also been...Novo NordiskSold as Ozempic and Rybelsus for diabetes.Apelin Receptor Agonist Azelaprag Can Effectively Combine with GLP-1 Drugs, Promoting Weight Loss While Preserving Muscle Mass. According to BioAge, in 8 Phase I Clinical Trials Involving 265 Patients, the Drug Was Found to Be Well-Tolerated.Company PipelinePreviously, BioAge received support from Eli Lilly to conduct a trial combining azelaprag with a major pharmaceutical company’s GLP-1/GIP receptor agonist, tizepatide, which is marketed as Mounjaro and Zepbound for diabetes and weight loss. Eli Lilly is currently conducting a Phase II trial of azelaprag and tizepatide, with results expected to be released in the third quarter of 2025.The company also plans to conduct a proof-of-concept trial for insulin sensitivity in the first half of next year, evaluating azelaprag as a monotherapy to support potential indication expansion. In addition, the company plans to apply for FDA approval in the second half of 2025 to initiate human testing of its NLRP3 inhibitor for metabolic diseases and neuroinflammation.AboutBioAgeBioAge Labs, Inc. was founded in 2015 as a biotechnology company currently in the Phase 2 clinical trial stage. It is dedicated to developing small-molecule therapies for metabolic diseases and is a startup focused on obesity treatment. The company gained prominence in 2020 by raising $90 million to target aging and age-related diseases.In February this year, BioAge raised another $170 million in a Series D funding round to leverage the potential of its apelin receptor agonist BGE-105 (azelaprag) in combination with GLP-1 drugs, aiming to develop a new generation of oral weight-loss medications while preserving muscle mass.August 22,BioAge AnnouncesFrontGSK's CEO Jean-Pierre Garnier has joined the company as Chairman of the Board.References:www.fiercebiotech.comwww.bioagelabs.comScan the WeChat QR code to add the editor of the Antibody Circle.Those who meet the requirements can join the Antibody Circle WeChat group!Please indicate: Name + Research Direction! All reproduced articles in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted can contact us (cbplib@163.com), and we will delete the content immediately. All articles represent the views of the author and do not represent the position of this website.
